Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
CML
•
Hematology
Do you recommend antimicrobial prophylaxis in patients with CML blast crisis after 7+3 induction while on maintenance TKI awaiting allo transplant?
Related Questions
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL?
In patients with CML who are receiving 1st line TKI with good molecular response, are you continuing therapy or switching to asciminib based on the ASC4FIRST data?
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
In patients with AML who achieve a CR with HMA/Ven, what is the optimal dose and schedule for venetoclax for further cycles?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
Are there different strategies you would utilize to monitor and manage potential resistance in patients with CML receiving asciminib?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
